References
- Ratjen F, Bell SC, Rowe SM, et al. Cystic fibrosis. Nat Rev Dis Prim. [cited 2019 Mar 13] 2015;1(1):15010.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/27189798
- Corcoran TE, Thomas KM, Myerburg MM, et al. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. Eur Respir J. [cited 2022 May 10] 2010;35(4):781–786.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/19717485/
- Sanders DB, Ostrenga JS, Rosenfeld M, et al. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. [cited 2019 Oct 23] 2020;19(3):407–414.InternetAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S156919931830763X
- Heltshe SL, Goss CH, Thompson V, et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. [cited 2021 Oct 30] 2016;71(3):223–229.InternetAvailable from: https://thorax.bmj.com/content/71/3/223
- Britto MT, Kotagal UR, Atherton HD, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64–72. DOI:10.1378/chest.121.1.64
- Sanders DB, Bittner RCL, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):393–400. DOI:10.1002/ppul.21374
- Sanders DB, Bittner RCL, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. [cited 2019 Mar 28] 2010;182(5):627–632.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/20463179
- Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010;45(2):127–134. DOI:10.1002/ppul.21117
- Regelmann WE, Schechter MS, Wagener JS, et al. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. Pediatr Pulmonol. [cited 2019 Jun 13] 2013;48(7):649–657.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/22949088
- Waters V, Ratjen F. Pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. [cited 2019 Oct 18] 2015;12 Suppl 2(Supplement 2):S200–6. InternetAvailable from http://www.ncbi.nlm.nih.gov/pubmed/26595740
- Wagener JS, Rasouliyan L, Vandevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2013;48(7):666–673. DOI:10.1002/ppul.22652
- Byrnes CA, Vidmar S, Cheney JL, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax. 2013;68(7):643–651. DOI:10.1136/thoraxjnl-2012-202342.
- Stanojevic S, McDonald A, Waters V, et al. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax. [cited 2019 Jun 13] 2017;72(4):327–332.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/27539619
- Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. [cited 2020 Oct 7] 2018;17(2):153–178. InternetAvailable from 10.1016/j.jcf.2018.02.006
- Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health [Internet]. Am J Respir Crit Care Med Am Thorac Soc. cited 2020 Jun 2 2013;187(7):680–689. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.201207-1160OE
- Smyth AR, Bell SC, Bojcin S, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. [cited 2019 May 15] 2014;13:S23–42. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/24856775
- Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis. Pediatrics. [cited 2019 Aug 2] 2016;137(4):e20151784.InternetAvailable from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2015-1784
- Rowbotham NJ, Smith S, Prayle AP, et al. Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review. Thorax. [cited 2021 Feb 23] 2018;74(3):229–236.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/30301819/
- Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis. JAMA. [cited 2019 Mar 20] 2012;307(21):2269–2277.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/22610452
- Saiman L. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa randomized controlled trial. JAMA. [[cited 2019 Feb 28]] 2010;303:1707. InternetAvailable from http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2010.563
- Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Paediatr. [cited 2019 Oct 24] 2001;139(3):359–365.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/11562614
- Bouzek DC, Ren CL, Thompson M, et al. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol. [cited 2022 Nov 5] 2022;57(7):1709–1716.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/35429154/
- Perrem L, Stanojevic S, Shaw M, et al. Lung clearance index to track acute respiratory events in school-age children with cystic fibrosis. Am J Respir Crit Care Med. [cited 2021 Jun 4] 2021;203(8):977–986.InternetAvailable from: https://www.atsjournals.org/doi/10.1164/rccm.202006-2433OC
- Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. J Am Med Assoc JAMA. 2012;307(21):2269–2277. DOI:10.1001/jama.2012.5214
- West NE, Beckett VV, Jain R, et al. Standardized treatment of pulmonary exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. [cited 2019 May 14] 2017;16(5):600–606.InternetAvailable from: https://www.sciencedirect.com/science/article/pii/S1569199317300991
- Perrem L, Stanojevic S, Shaw M, et al. Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis. J Cyst Fibros. [[cited 2022 Sep 10]; Available from] 2022;Internet: https://pubmed.ncbi.nlm.nih.gov/35753986/
- Kraynack NC, Gothard MD, Falletta LM, et al. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centers. Pediatr Pulmonol. [cited 2019 Oct 23] 2011;46(9):870–881.InternetAvailable from: https://onlinelibrary.wiley.com/doi/10.1002/ppul.21442
- Currie G, Tai A, Snelling T, et al. Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians. BMJ Open Respir Res. [cited 2022 Nov 5] 2021;8(1):e000956.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/34266854/
- Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. [cited 2019 Jun 13] 2012;40(1):61–66.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/22135280
- Cheney J, Vidmar S, Gailer N, et al. Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes. J Cyst Fibros. [cited 2022 Oct 18] 2020;19(3):483–491.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/32165156/
- Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med. [cited 2022 Oct 18] 2005;172(1):99–104.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/15831839/
- Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. [cited 2022 Oct 18] 2005;146(5):681–687.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/15870674/
- Begum N, Byrnes CA, Cheney J, et al. Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. J Cyst Fibros Internet. [cited 2022 Aug 15]; Available from 2022;21(6):977–983. https://pubmed.ncbi.nlm.nih.gov/35341694/
- Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. [cited 2022 Oct 18] 2007;175(8):822–828.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/17234902/
- Goss CH, Burns JL. Exacerbations in cystic fibrosis·1: epidemiology and pathogenesis. Thorax. 2007;62(4):360–367. DOI:10.1136/thx.2006.060889.
- Van Ewijk BE, Der Zalm MM V, Wolfs TFW, et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics. [cited 2022 Oct 17] 2008;122(6):1171–1176.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/19047230/
- Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. [cited 2022 Oct 17] 2012;11(5):433–439.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/22579414/
- Meyer VMC, Siqueira MM, Costa PFBM, et al. Clinical impact of respiratory virus in pulmonary exacerbations of children with cystic fibrosis. PLoS ONE. [cited 2022 Oct 17] 2020;15(10):e0240452.InternetAvailable from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240452
- Esther CR, Lin FC, Kerr A, et al. Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol. [cited 2022 Oct 17] 2014;49(9):926–931.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/24167159/
- Caverly LJ, VanDevanter DR. The elusive role of airway infection in cystic fibrosis exacerbation. J Pediatric Infect Dis Soc InternetAvailable from. [cited 2022 Oct 17] 2022;11(Supplement_2):S40–45. https://academic.oup.com/jpids/article/11/Supplement_2/S40/6693711
- Perrem L, Ratjen F. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Pediatr Pulmonol. [cited 2019 Nov 28] 2019;54(Suppl 3):S46–55. InternetAvailable from http://www.ncbi.nlm.nih.gov/pubmed/31715088
- Ishak A, Stick SM, Turkovic L, et al. BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis. Chest. [cited 2022 Oct 18] 2020;158(6):2314–2322.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/32622821/
- Ratjen F, Waters V, Klingel M, et al. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016;47(3):829 LP–836. InternetAvailable from: http://erj.ersjournals.com/content/47/3/829.abstract
- Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest. 2007;132(4):1212–1218. DOI:10.1378/chest.07-0843
- Davis CS, Faino AV, Onchiri F, et al. Systemic corticosteroids in the management of pediatric cystic fibrosis pulmonary exacerbations. Ann Am Thorac Soc. 2022. [cited 2022 Nov 5]; Available from. Internet https://pubmed.ncbi.nlm.nih.gov/36044723/
- Prednisone in cystic fibrosis pulmonary exacerbations - full text view. ClinicalTrials.gov [Internet]. [cited 2022 Oct 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03070522.
- Sanders DB, Wu R, O’Neil T, et al. Changes in Care during the COVID-19 pandemic for people with cystic fibrosis. Ann Am Thorac Soc. [cited 2022 Oct 19] 2022;19(10):1697–1703.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/35143374/
- Dixon E, Dick K, Ollosson S, et al. Telemedicine and cystic fibrosis: do we still need face-to-face clinics? Paediatr Respir Rev. [cited 2022 Oct 19] 2022;42:23–28. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/34215541/
- Ong T, Van Citters AD, Dowd C, et al. Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros. 2021;20:57–63.
- Stanojevic S, Ratjen F. Physiologic endpoints for clinical studies for cystic fibrosis. J Cyst Fibros InternetAvailable from. 2016 [[cited 2019 May 8]];15(4):416–423. DOI:10.1016/j.jcf.2016.05.014.
- Morgan WJ, Wagener JS, Pasta DJ, et al. Relationship of antibiotic treatment to recovery after acute FEV 1 decline in children with cystic fibrosis. Ann Am Thorac Soc. [cited 2020 Mar 11] 2017;14(6):937–942.InternetAvailable from: http://www.atsjournals.org/doi/10.1513/AnnalsATS.201608-615OC
- Stanojevic S, Filipow N, Ratjen F. Paediatric reproducibility limits for the forced expiratory volume in 1 s. Thorax. [cited 2022 Sep 10] 2020;75(10):891–896. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/32788261/
- Rayment JH, Stanojevic S, Davis SD, et al. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. Thorax. [cited 2019 May 8] 2018;73(5):451–458.InternetAvailable from: http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2017-210979
- Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration. [cited 2019 May 15] 2009;78(3):339–355. InternetAvailable from https://www.karger.com/Article/FullText/225373
- Aurora P, Kozlowska W, Stocks J. Gas mixing efficiency from birth to adulthood measured by multiple-breath washout. Respir Physiol Neurobiol. cited 2020 Apr 1 2005;148(1–2):125–139. InternetAvailable from https://linkinghub.elsevier.com/retrieve/pii/S1569904805001576
- Horsley AR, Belcher J, Bayfield K, et al. Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis. Thorax [Internet]. 2021 [cited 2021 Jul 26];thoraxjnl-2021-216928. Available from: https://pubmed.ncbi.nlm.nih.gov/34301741/.
- Sandvik RM, Kongstad T, Green K, et al. Prospective longitudinal association between repeated multiple breath washout measurements and computed tomography scores in children with cystic fibrosis. J Cyst Fibros. 2020 [[cited 2020 Oct 5]];2121. InternetAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S1569199320308717
- Perrem L, Stanojevic S, Solomon M, et al. Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls. Thorax. 2022. cited 2022 Apr 21. Internetthoraxjnl-2021-218347Available from https://pubmed.ncbi.nlm.nih.gov/35428702/
- Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. [cited 2022 Oct 17] 1999;28(5):321–328.InternetAvailable from: https://onlinelibrary.wiley.com/terms-and-conditions
- Breuer O, Caudri D, Akesson L, et al. The clinical significance of oropharyngeal cultures in young children with cystic fibrosis. Eur Respir J. 2018;51(5):51. DOI:10.1183/13993003.00238-2018
- Armstrong DS, Grimwood K, Carlin JB, et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267–275. DOI:10.1002/(SICI)1099-0496(199605)21:5<267:AID-PPUL1>3.0.CO;2-K
- Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage–directed therapy on pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis. JAMA. 2011;306(2):163–171. DOI:10.1001/jama.2011.954
- Ronchetti K, Tame JD, Paisey C, et al. The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. 2018;6(6):461–471. DOI:10.1016/S2213-2600(18)30171-1
- Greene KE, Takasugi JE, Godwin JD, et al. Radiographic changes in acute exacerbations of cystic fibrosis in adults: a pilot study. AJR Am J Roentgenol. [cited 2022 Oct 19] 1994;163(3):557–562.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/8079843/
- Rayment JH, Couch MJ, McDonald N, et al. Hyperpolarised 129Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis. Eur Respir J. [cited 2020 Jan 8] 2019;53(5):1802188.InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/30819815
- Sanders DB, Solomon GM, Beckett VV, et al. Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. [cited 2019 May 14] 2017;16(5):592–599.InternetAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S1569199317301017
- Hoppe JE, Wagner BD, Accurso FJ, et al. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. [cited 2022 Oct 18] 2018;17(6):760–768.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/29921503/
- Zemanick E, Burgel PR, Taccetti G, et al. Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices. J Cyst Fibros. [cited 2022 Oct 19] 2020;19(3):370–375.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/31680041/
- VanDevanter DR, West NE, Sanders DB, et al. Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros. [cited 2022 Nov 5] 2022;21(5):753–758.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/35466039/
- Somayaji R, Parkins MD, Shah A, et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review. J Cyst Fibros. [cited 2022 Oct 19] 2019;18(2):236–243.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/30709744/
- Ng C, Nadig T, Smyth AR, et al. Current opinion in pulmonary medicine – Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. [cited 2022 Oct 19] 2020;26(6):679. InternetAvailable from:/pmc/articles/PMC7958864/ 10.1097/MCP.0000000000000730
- Blanchard AC, Horton E, Stanojevic S, et al. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017;16(3):395–400. DOI:10.1016/j.jcf.2017.01.007
- Noah TL, Ivins SS, Abode KA, et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol. [cited 2022 Oct 25] 2010;45(3):281–290.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/20146365/
- Dentice RL, Elkins MR, Middleton PG, et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax. [cited 2023 Jan 16] 2016;71(2):141–147.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/26769016/
- Wilmott RW, Amin RS, Colin AA, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med. [cited 2023 Jan 16] 1996;153(6):1914–1917.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/8665055/
- Goss CH, Heltshe SL, West NE, et al. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. Am J Respir Crit Care Med. [cited 2021 Oct 31] 2021;204(11):1295–1305.InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/34469706/
- Yang C, Montgomery M. Dornase alfa for cystic fibrosis. In: Cochrane Database Syst (Rev). John Wiley and Sons Ltd; 2018.
- Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–1948. InternetAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619325978
- Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. [cited 2021 Mar 24] 2019;381(19):1809–1819.InternetAvailable from: http://www.nejm.org/doi/10.1056/NEJMoa1908639
- A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function - full text view ClinicalTrials.gov [Internet]. [cited 2022 Jun 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04038047.
- A real-world study in cystic fibrosis [Internet]. [cited 2022 Jun 21]. Available from: https://recovercf.ie/.
- Nichols DP, Paynter AC, Heltshe SL, et al. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis a clinical trial. Am J Respir Crit Care Med. [cited 2022 Jun 14] 2022;205(5):529–539.InternetAvailable from: www.clinicaltrials.gov
- Cogen JD, Kahl BC, Maples H, et al. Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros. [cited 2020 Mar 3] 2020;19(4):511–520.InternetAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S156919932030059X
- Antibiotic dosing guideline for cystic fibrosis [Internet]. Available from: https://urldefense.com/v3/__https://www.cysticfibrosis.ca__;!!D0zGoin7BXfl!_4fCneRKHBi7qvYHWT9mEaL6d2eaYUaIW6ejzXSZ2uxvuNagmBlLF6Fd5scl8zbuhnlv4seLWo5Mc6ketNvRcuCBFo6yBcLxBpM$.